systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-721Research ArticleСТАТЬИARTICLESВозможности коррекции гиперурикемии лозартаном у пациентов с артериальной гипертензией и подагройНедогодаС. В.noemail@neicon.ruЛедяеваА. А.noemail@neicon.ruЧумачокЕ. В.noemail@neicon.ruЦомаВ. В.noemail@neicon.ruВолгоградский государственный медицинский университетRussian Federation201109022023846468Copyright © Недогода С.В., Ледяева А.А., Чумачок Е.В., Цома В.В., 20232023Недогода С.В., Ледяева А.А., Чумачок Е.В., Цома В.В.Недогода С.В., Ледяева А.А., Чумачок Е.В., Цома В.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/721ReferencesAlderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002; 2: 126-30.Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002; 2: 126-30.Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg. Sweden. Acta Med Scand 1988; 224: 549-55.Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg. Sweden. Acta Med Scand 1988; 224: 549-55.Ford ES, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526-32.Ford ES, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526-32.Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20 (3): 369-79.Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20 (3): 369-79.Bulpitt CJ. Serum uric acid in hypertensive patients. Br Heart J 1975; 37: 1210-5.Bulpitt CJ. Serum uric acid in hypertensive patients. Br Heart J 1975; 37: 1210-5.Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.Niskanen LK, Laaksonen DE, Nyyssonen K et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-51.Niskanen LK, Laaksonen DE, Nyyssonen K et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-51.Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-6.Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-6.Bairaktari ET, Kakafika AI, Pritsivelis N et al. Hypouricemia in individuals admitted to an inpatient hospital-based facility. Am J Kidney Dis 2003; 41: 1225-32.Bairaktari ET, Kakafika AI, Pritsivelis N et al. Hypouricemia in individuals admitted to an inpatient hospital-based facility. Am J Kidney Dis 2003; 41: 1225-32.Riedel A, Nelson M. Prevalence of co morbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10 (6): 308-14.Riedel A, Nelson M. Prevalence of co morbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10 (6): 308-14.Hamada T, Hisatome I, Kinugasa Y et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002; 41: 793-7.Hamada T, Hisatome I, Kinugasa Y et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002; 41: 793-7.Shahinfar S, Simpson R, Carides A et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN 1997; 8: 322.Shahinfar S, Simpson R, Carides A et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN 1997; 8: 322.Shahinfar S, Simpson RL, Carides AD et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999; 56: 1879-85.Shahinfar S, Simpson RL, Carides AD et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999; 56: 1879-85.Daskalopoulou SS et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66 (4): 1714-5.Daskalopoulou SS et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66 (4): 1714-5.Daijiro U, Hiroaki K. Long-term effects of angiotensin II receptor antagonist losartan on uric acid metabolism in hyperuricemic patients. Gout Nucleic Acid Metab 2002; 26: 25-32.Daijiro U, Hiroaki K. Long-term effects of angiotensin II receptor antagonist losartan on uric acid metabolism in hyperuricemic patients. Gout Nucleic Acid Metab 2002; 26: 25-32.Quarantino CP, Di Sciacio N, Rucci C et al. The normal range of serum urate levels and of fractional urate excretion. Adv Exp Med Biol 1994; 370: 91-3.Quarantino CP, Di Sciacio N, Rucci C et al. The normal range of serum urate levels and of fractional urate excretion. Adv Exp Med Biol 1994; 370: 91-3.Takahashi S, Moriwaki Y. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62: 572-5.Takahashi S, Moriwaki Y. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62: 572-5.
The authors declare that there are no conflicts of interest present.